eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

Review paper
Leflunomide safety profile

Bożena Targońska-Stępniak

Reumatologia 2008; 46, 6: 367–371
Online publish date: 2009/01/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Leflunomide (LEF) is one of the disease-modifying antirheumatic drugs (DMARDs) used in the treatment of rheumatoid and psoriatic arthritis. Results of clinical trials and post-marketing studies documented that LEF is effective in reducing disease activity and improving quality of life. The safety data show no increased risk of adverse events during LEF treatment, in comparison with other DMARDs. The incidence of adverse events during LEF therapy is not significantly different from that observed with methotrexate or sulfasalazine treatment. The most common LEF-associated adverse events include: diarrhoea, elevated liver enzymes, alopecia and rash. Adverse events are usually observed during the first 1-3 months of therapy. Careful monitoring of liver function tests and complete blood cell count is necessary during LEF therapy, especially within the first
6 months of treatment.
keywords:

disease-modifying antirheumatic drugs, leflunomide, arthritis, safety



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe